| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g | |||
| Other Sizes |
| Targets |
Nicotinamide Riboside Chloride functions as a precursor to nicotinamide adenine dinucleotide (NAD+), a critical coenzyme involved in cellular metabolism, energy production, and redox reactions. By increasing NAD+ levels, the compound activates sirtuins SIRT1 and SIRT3, which are NAD+-dependent deacetylases involved in regulating oxidative metabolism, stress responses, and longevity. The compound also restores antiviral poly(ADP-ribose) polymerase (PARP) functions to support innate immunity. Its primary target is the NAD+ biosynthesis pathway, specifically the nicotinamide riboside kinase (NRK) pathway.
|
|---|---|
| ln Vitro |
Nicotinamide riboside Chloride (0.5 nM; 24 hours) decreases Ndufa9 and SOD2 acetylation [1]. In C2C12, Hepa1.6, and HEK293 cells, nicotinamide riboside chloride raises intracellular and mitochondrial NAD+ levels in a concentration-dependent manner within the concentration range of 1-1000 μM [1]. Innate immunity against the coronavirus (CoV), which causes COVID-19, is supported by chlorinated nicotinamide riboside, which also increases NAD and restores antiviral poly(ADP-ribose) polymerase (PARP) function [3].
In vitro studies demonstrate that Nicotinamide Riboside Chloride (0.5 nM; 24 hours) decreases acetylation of Ndufa9 and SOD2, indicating increased NAD+-dependent deacetylase activity. In C2C12, Hepa1.6, and HEK293 cells, the compound raises intracellular and mitochondrial NAD+ levels in a concentration-dependent manner within the 1-1000 μM range. The compound supports innate immunity against coronavirus (CoV) by increasing NAD and restoring antiviral PARP function. It enhances oxidative metabolism and provides protection against high fat diet-induced metabolic abnormalities. |
| ln Vivo |
Nicotinamide riboside chloride oral supplementation (400 mg/kg/day) for 16 weeks enhances intracellular and plasma NAD+ levels in a tissue-specific manner [1].
In vivo studies show that oral supplementation of Nicotinamide Riboside Chloride (400 mg/kg/day) for 16 weeks enhances intracellular and plasma NAD+ levels in a tissue-specific manner in C57Bl/6J mice. The compound reduces cognitive deterioration in a transgenic mouse model of Alzheimer's disease. By boosting NAD+ levels, it plays a role in promoting cellular repair, enhancing metabolic function, and supporting healthy aging. The compound has shown protection against high fat diet-induced metabolic abnormalities and may have applications in metabolic and neurodegenerative diseases. |
| Enzyme Assay |
The in vitro enzyme/receptor binding assay for Nicotinamide Riboside Chloride involves measuring NAD+ levels in cell lysates using enzymatic cycling assays or LC-MS/MS. Cells are treated with the compound at concentrations ranging from 1-1000 μM for 24 hours. NAD+ and NADH levels are quantified using colorimetric or fluorometric methods. SIRT1 and SIRT3 activity is measured using fluorogenic peptide substrates in the presence of NAD+. PARP activity is assessed by measuring poly(ADP-ribose) formation. Acetylation status of target proteins (Ndufa9, SOD2, PGC-1α) is evaluated by Western blot using acetyl-lysine antibodies.
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: HEK293T Cell Tested Concentrations: 0.5 nM Incubation Duration: 24 hrs (hours) Experimental Results: diminished acetylation status of Ndufa9 and SOD2. In vitro cellular assays for Nicotinamide Riboside Chloride typically use C2C12 myotubes, Hepa1.6 hepatoma cells, and HEK293 kidney cells. Cells are treated with the compound at concentrations of 1-1000 μM for 24-72 hours. NAD+ levels are measured using NAD+/NADH quantification kits. Mitochondrial function is assessed by Seahorse metabolic flux analysis measuring oxygen consumption rate (OCR) and extracellular acidification rate (ECAR). SIRT1 and SIRT3 activation is confirmed by Western blot analysis of acetylation targets. Cell viability is assessed using MTT assays. PARP activity is measured after viral infection or DNA damage induction. |
| Animal Protocol |
Animal/Disease Models: 10weeks old C57Bl/6J mice [1]
Doses: 400 mg/kg Route of Administration: PO; daily; continued for 16 weeks Experimental Results: Plasma and intracellular NAD+ content increased in a tissue-specific manner. In vivo animal studies for Nicotinamide Riboside Chloride involve 10-week-old C57Bl/6J mice administered 400 mg/kg orally daily for 16 weeks. Plasma and tissue NAD+ levels are measured at various time points. For Alzheimer's disease models, transgenic mice are treated with the compound for several months and cognitive function is assessed using Morris water maze or novel object recognition tests. For metabolic studies, mice are fed high-fat diets and treated with the compound to evaluate protection against metabolic abnormalities. Endpoints include body weight, glucose tolerance, insulin sensitivity, and tissue histology. |
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Nicotinamide Riboside Chloride indicate good oral bioavailability. The compound is soluble in DMSO and water (10 mg/mL). It appears as a white to yellow solid powder. The compound has hydrogen bond donors (4), hydrogen bond acceptors (6), and rotatable bonds (3). The CAS number is 23111-00-4 and molecular weight is 290.7. After oral administration, the compound is rapidly absorbed and converted to NAD+ via the NRK pathway. NAD+ levels peak within hours of administration. The compound should be stored at -20°C for long-term preservation.
|
| Toxicity/Toxicokinetics |
Toxicological data for Nicotinamide Riboside Chloride indicates it is generally well-tolerated. As a form of vitamin B3, it has a favorable safety profile. However, high doses may cause side effects similar to niacin, including flushing, gastrointestinal discomfort, and headache. The compound is for research use only and not for human therapeutic applications. Standard safety precautions should be followed when handling. Long-term toxicity studies in animal models have not shown significant adverse effects at the doses tested. For detailed toxicity information, safety data sheets should be consulted.
|
| References |
|
| Additional Infomation |
Nicotinamide nucleoside chloride is an N-glycosyl compound.
Nicotinamide Riboside Chloride (also known as N-Ribosylnicotinamide chloride, Nicotinamide-beta-riboside chloride, NR chloride) is a research-grade compound with a purity of ≥98%. Its CAS number is 23111-00-4. The compound is an orally bioactive NAD+ precursor and vitamin B3 source. It increases NAD+ levels and activates SIRT1 and SIRT3, enhancing oxidative metabolism. The compound is used in research on aging, metabolic disorders, neurodegenerative diseases, and immune function. It has not been approved by the FDA for therapeutic use and is strictly for research purposes only. |
| Molecular Formula |
C11H15CLN2O5
|
|---|---|
| Molecular Weight |
290.7
|
| Exact Mass |
290.067
|
| CAS # |
23111-00-4
|
| Related CAS # |
Nicotinamide riboside;1341-23-7;Nicotinamide riboside tartrate;2415657-86-0;Nicotinamide riboside malate;2415659-01-5
|
| PubChem CID |
90480033
|
| Appearance |
White to yellow solid powder
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
19
|
| Complexity |
314
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N.[Cl-]
|
| InChi Key |
YABIFCKURFRPPO-IVOJBTPCSA-N
|
| InChi Code |
InChI=1S/C11H14N2O5.ClH/c12-10(17)6-2-1-3-13(4-6)11-9(16)8(15)7(5-14)18-11;/h1-4,7-9,11,14-16H,5H2,(H-,12,17);1H/t7-,8-,9-,11-;/m1./s1
|
| Chemical Name |
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxamide;chloride
|
| Synonyms |
N-Ribosylnicotinamide chlorideNicotinamide-beta-riboside chloride Nicotinamide ribonucleoside chloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~125 mg/mL (~430.00 mM)
DMSO : ~50 mg/mL (~172.00 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 25 mg/mL (86.00 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4400 mL | 17.1999 mL | 34.3997 mL | |
| 5 mM | 0.6880 mL | 3.4400 mL | 6.8799 mL | |
| 10 mM | 0.3440 mL | 1.7200 mL | 3.4400 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
